{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:03:03Z","timestamp":1788901383919,"version":"build-2803163510"},"reference-count":107,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Science and Innovation (MICINN)","award":["PID2020-119298RB-I00"],"award-info":[{"award-number":["PID2020-119298RB-I00"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>In the adult population, community-acquired pneumonia (CAP) is a serious disease that is responsible for high morbidity and mortality rates, being frequently associated with multidrug resistant pathogens. The aim of this review is to update a practical immunization prevention guideline for CAP in Spain caused by prevalent respiratory pathogens, based on the available scientific evidence through extensive bibliographic review and expert opinion. The emergence of COVID-19 as an additional etiological cause of CAP, together with the rapid changes in the availability of vaccines and recommendations against SARS-CoV-2, justifies the need for an update. In addition, new conjugate vaccines of broader spectrum against pneumococcus, existing vaccines targeting influenza and pertussis or upcoming vaccines against respiratory syncytial virus (RSV) will be very useful prophylactic tools to diminish the burden of CAP and all of its derived complications. In this manuscript, we provide practical recommendations for adult vaccination against the pathogens mentioned above, including their contribution against antibiotic resistance. This guide is intended for the individual perspective of protection and not for vaccination policies, as we do not pretend to interfere with the official recommendations of any country. The use of vaccines is a realistic approach to fight these infections and ameliorate the impact of antimicrobial resistance. All of the recently available scientific evidence included in this review gives support to the indications established in this practical guide to reinforce the dissemination and implementation of these recommendations in routine clinical practice.<\/jats:p>","DOI":"10.3390\/antibiotics12010138","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T03:02:06Z","timestamp":1673319726000},"page":"138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-979X","authenticated-orcid":false,"given":"Esther","family":"Redondo","sequence":"first","affiliation":[{"name":"Infectious, Migrant, Vaccines and Preventive Activities Group of SEMERGEN, International Healthcare Center of Ayuntamiento de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-9264","authenticated-orcid":false,"given":"Irene","family":"Rivero-Calle","sequence":"additional","affiliation":[{"name":"Translational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Cl\u00ednico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Vaccines, Infections and Pediatrics Research Group (GENVIP), Healthcare Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-6175","authenticated-orcid":false,"given":"Enrique","family":"Mascar\u00f3s","sequence":"additional","affiliation":[{"name":"Health Department, Hospital la Fe, Primary Care Center Arquitecto Tols\u00e1, 46019 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3579-6814","authenticated-orcid":false,"given":"Daniel","family":"Oca\u00f1a","sequence":"additional","affiliation":[{"name":"Primary Care Health Care Center Algeciras, 11204 Algeciras, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Jimeno","sequence":"additional","affiliation":[{"name":"Primary Care Health Center Isla de Oza, Vaccine Responsible of SEMG, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-7101","authenticated-orcid":false,"given":"\u00c1ngel","family":"Gil","sequence":"additional","affiliation":[{"name":"CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Preventive and Public Health Department, Rey Juan Carlos University, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"D\u00edaz-Maroto","sequence":"additional","affiliation":[{"name":"Primary Care Health Center Guadalajara, Infectious Diseases Group SEMERGEN, 19161 Guadalajara, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Linares","sequence":"additional","affiliation":[{"name":"Infectious Diseases Group SEMERGEN, Fundaci\u00f3n iO, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Onieva-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Preventive Medicine Department, Hospital Costa del Sol, 29603 Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonz\u00e1lez-Romo","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Health Research Institute (IdISSC), Hospital Cl\u00ednico San Carlos, School of Medicine, Complutense University of Madrid (UCM), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-0837","authenticated-orcid":false,"given":"Jos\u00e9","family":"Yuste","sequence":"additional","affiliation":[{"name":"CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"National Center for Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[{"name":"Translational Pediatrics and Infectious Diseases Section, Pediatrics Department, Hospital Cl\u00ednico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Vaccines, Infections and Pediatrics Research Group (GENVIP), Healthcare Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1513\/AnnalsATS.201312-420PS","article-title":"Lung disease in a global context. A call for public health action","volume":"11","author":"Schluger","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates","volume":"374","author":"Wolfson","year":"2009","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(06)69334-3","article-title":"Pneumonia: The leading killer of children","volume":"368","author":"Wardlaw","year":"2006","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","article-title":"Global, regional, and national causes of under-5 mortality in 2000-15: An updated systematic analysis with implications for the Sustainable Development Goals","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020\u20132021","volume":"399","author":"Collaborators","year":"2022","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"o1755","DOI":"10.1136\/bmj.o1755","article-title":"COVID-19: Antimicrobial resistance rose dangerously in US during pandemic, CDC says","volume":"378","author":"Tanne","year":"2022","journal-title":"BMJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid2811.220415","article-title":"Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic","volume":"28","author":"Thomas","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2666-5247(22)00127-6","article-title":"Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004\u20132020: A national surveillance study","volume":"3","author":"Sempere","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/14760584.2018.1525298","article-title":"Influenza vaccination and prevention of antimicrobial resistance","volume":"17","author":"Esposito","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nm.4465","article-title":"The role of vaccines in preventing bacterial antimicrobial resistance","volume":"24","author":"Jansen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00428-16","DOI":"10.1128\/mBio.00428-16","article-title":"How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?","volume":"7","author":"Lipsitch","year":"2016","journal-title":"mBio"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1176","DOI":"10.1016\/S2214-109X(17)30364-9","article-title":"Vaccination to reduce antimicrobial resistance","volume":"5","author":"Ginsburg","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2214-109X(18)30043-3","article-title":"Vaccination to reduce antimicrobial resistance","volume":"6","author":"Atkins","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S1473-3099(17)30478-4","article-title":"Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance","volume":"18","author":"Atkins","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/jac\/dkab482","article-title":"A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain","volume":"77","author":"Sempere","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.vaccine.2011.03.059","article-title":"Ten years of Hib vaccination in Italy: Prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance","volume":"29","author":"Giufre","year":"2011","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3389\/fimmu.2018.02700","article-title":"Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract","volume":"9","author":"Domenech","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.4638","article-title":"1918 pandemic influenza virus and Streptococcus pneumoniae co-infection results in activation of coagulation and widespread pulmonary thrombosis in mice and humans","volume":"238","author":"Walters","year":"2016","journal-title":"J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bosch, A.A., Biesbroek, G., Trzcinski, K., Sanders, E.A., and Bogaert, D. (2013). Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003057"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1086\/591708","article-title":"Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness","volume":"198","author":"Morens","year":"2008","journal-title":"J. Infect Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Opatowski, L., Baguelin, M., and Eggo, R.M. (2018). Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006770"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1128\/IAI.00155-09","article-title":"Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules","volume":"77","author":"Zarantonelli","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gramegna, A., Sotgiu, G., Di Pasquale, M., Radovanovic, D., Terraneo, S., Reyes, L.F., Vendrell, E., Neves, J., Menzella, F., and Blasi, F. (2018). Atypical pathogens in hospitalized patients with community-acquired pneumonia: A worldwide perspective. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3565-z"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.medcli.2020.05.022","article-title":"Pneumococcal superinfection in COVID-19 patients: A series of 5 cases","volume":"155","author":"Cucchiari","year":"2020","journal-title":"Med. Clin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1002\/ppul.24916","article-title":"SARS-CoV-2 and Streptococcus pneumoniae coinfection as a cause of severe pneumonia in an infant","volume":"55","author":"Ecclesia","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3201\/eid2005.131528","article-title":"Trends in infectious disease mortality rates, Spain, 1980\u20132011","volume":"20","author":"Llacer","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semerg.2016.07.009","article-title":"Vaccination against community acquired pneumonia in adult patients. A position paper by Neumoexpertos en Prevencion","volume":"42","author":"Redondo","year":"2016","journal-title":"Semergen"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.semerg.2018.09.005","article-title":"Adult community acquired pneumonia vaccination: 2018 Update of the positioning of the Pneumonia Prevention Expert Group","volume":"44","author":"Redondo","year":"2018","journal-title":"Semergen"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semerg.2021.06.005","article-title":"Vaccination against community acquired pneumonia in adults. Update 2021 of the position paper by Neumoexpertos en Prevencion Group","volume":"47","author":"Redondo","year":"2021","journal-title":"Semergen"},{"key":"ref_31","unstructured":"OCEBM Levels of Evidence (2022, October 29). The 2011 Oxford CEBM Levels of Evidence (Introductory Document). Available online: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1016\/j.vaccine.2018.10.015","article-title":"Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: A retrospective database analysis","volume":"36","author":"Yang","year":"2018","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.vaccine.2022.03.005","article-title":"Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination","volume":"40","author":"Morga","year":"2022","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e3778","DOI":"10.1093\/cid\/ciaa1483","article-title":"Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era","volume":"73","author":"Domenech","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/cid\/ciab307","article-title":"The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011\u20132018","volume":"73","author":"Torres","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"De Miguel, S., Latasa, P., Yuste, J., Garcia, L., Ordobas, M., Ramos, B., Perez, M., Ortiz, M.A., and Sanz, J.C. (2021). Age-Dependent Serotype-Associated Case-Fatality Rate in Invasive Pneumococcal Disease in the Autonomous Community of Madrid between 2007 and 2020. Microorganisms, 9.","DOI":"10.3390\/microorganisms9112286"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Aguinagalde, L., Corsini, B., Domenech, A., Domenech, M., Camara, J., Ardanuy, C., Garcia, E., Linares, J., Fenoll, A., and Yuste, J. (2015). Emergence of Amoxicillin-Resistant Variants of Spain9V-ST156 Pneumococci Expressing Serotype 11A Correlates with Their Ability to Evade the Host Immune Response. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137565"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_39","unstructured":"WHO (2022, October 29). Influenza Update N\u00b0 432. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/influenza-updates\/2022\/2022_11_14_surveillance_update_432.pdf?sfvrsn=19cda949_1&download=true."},{"key":"ref_40","unstructured":"SVGE (2022, October 29). Vigilancia Centinela de Infecci\u00f3n Respiratoria Aguda en Atenci\u00f3n Primaria (IRAs) y en Hospitales (IRAG) Gripe, COVID-19 y Otros Virus Respiratorio. Available online: https:\/\/vgripe.isciii.es\/documentos\/20202021\/boletines\/Informe%20semanal%20SVGE%20y%20otros%20virus%20respiratorios_2020-2021_202021.pdf."},{"key":"ref_41","unstructured":"SIVIRA (2022, October 29). Vigilancia Centinela de Infecci\u00f3n Respiratoria Aguda en Atenci\u00f3n Primaria (IRAs) y en Hospitales (IRAG) Gripe, COVID-19 y Otros Virus Respiratorio. Available online: https:\/\/vgripe.isciii.es\/documentos\/20212022\/boletines\/Informe%20semanal_SiVIRA_392022.pdf."},{"key":"ref_42","unstructured":"WEP, and Global Infrastructure Partners (2022, October 29). Review of Global Influenza Circulation, Late 2019 to 2020, and the Impact of the COVID-19 Pandemic on Influenza Circulation. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer-9625-241-264."},{"key":"ref_43","unstructured":"GISRS-WHO (2022, October 29). Virus Detection by Subtype Reported to FLUNET. Available online: https:\/\/app.powerbi.com\/view?r=eyJrIjoiZTkyODcyOTEtZjA5YS00ZmI0LWFkZGUtODIxNGI5OTE3YjM0IiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9."},{"key":"ref_44","unstructured":"Assembly, W. (2022, October 29). Prevention and Control of Influenza Pandemics and Annual Epidemics. Available online: https:\/\/apps.who.int\/gb\/archive\/pdf_files\/WHA56\/ea56r19.pdf."},{"key":"ref_45","unstructured":"SIVAMIN (2022, October 29). Sistema de Informaci\u00f3n de Vacunaciones. Available online: https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/S\/sivamin."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Diez-Domingo, J., Redondo Marguello, E., Ortiz de Lejarazu Leonardo, R., Gil de Miguel, A., Guillen Ortega, J.M., Rincon Mora, J., and Martinon-Torres, F. (2022). A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018-19 season: The Gripometro. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-13193-x"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Gil-de-Miguel, \u00c1., Martin\u00f3n-Torres, F., D\u00edez-Domingo, J., de Lejarazu Leonardo, R.O., Pumarola, T., Carmo, M., Drago, G., L\u00f3pez-Belmonte, J.L., Bricout, H., and de Courville, C. (2022). Clinical and economic burden of physician-diagnosed influenza in adults during the 2017\/2018 epidemic season in Spain. BMC Public Health., 22.","DOI":"10.1186\/s12889-022-14732-2"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s41669-022-00329-3","article-title":"Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain","volume":"6","author":"Callejo","year":"2022","journal-title":"Pharmacoecon. Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.121.057042","article-title":"Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial","volume":"144","author":"Frobert","year":"2021","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e228873","DOI":"10.1001\/jamanetworkopen.2022.8873","article-title":"Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis","volume":"5","author":"Behrouzi","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_51","first-page":"e2149","article-title":"Influenza Vaccination and Risk of Ischemic Stroke: A Population-Based Case-Control Study","volume":"99","author":"Gil","year":"2022","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chen, C.C., Chou, K.T., Liu, J.C., Chiu, C.C., Yang, T.Y., Lin, C.H., Fang, Y.A., Jian, W., Lei, M.H., and Yeh, H.T. (2022). Association between Stroke Risk and Influenza Vaccination in Patients with Gout: A Nationwide Population-Based Study. Vaccines, 10.","DOI":"10.3390\/vaccines10081278"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1159\/000519469","article-title":"Associations between Combined Influenza and Pneumococcal Pneumonia Vaccination and Cardiovascular Outcomes","volume":"146","author":"Ma","year":"2021","journal-title":"Cardiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciaa564","article-title":"Effect of Influenza Vaccination in Preventing Laboratory-Confirmed Influenza Hospitalization in Patients With Diabetes Mellitus","volume":"73","author":"Navascues","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1932296819883340","article-title":"Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact","volume":"15","author":"Samson","year":"2021","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_56","unstructured":"AEP (2022, October 29). Vacunaci\u00f3n Frente a la Gripe Estacional en la Infancia y la Adolescencia, 2022\u20132023. Available online: https:\/\/vacunasaep.org\/sites\/vacunasaep.org\/files\/gripe_recomendaciones-vacunacion-antigripal_2022-2023_v.2_22sep2022_0.pdf."},{"key":"ref_57","unstructured":"CIMA (2022, October 29). Ficha Tecnica Fluenz Tetra Suspension Para Pulverizacion Nasal. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/113887003\/FT_113887003.html."},{"key":"ref_58","unstructured":"Sanidad, M.D. (2022, October 29). Recomendaciones de Vacunaci\u00f3n Frente a la Gripe en Poblaci\u00f3n Infantil de 6 a 59 Meses. Available online: https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/docs\/Recomendaciones_vacunacion_gripe_PoblacionInfantil.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(22)00383-X","article-title":"SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses","volume":"399","author":"Swets","year":"2022","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virol.2022.09.009","article-title":"SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021\u20132022 influenza season","volume":"576","author":"Tang","year":"2022","journal-title":"Virology"},{"key":"ref_61","unstructured":"National Centre for Immunisation Research and Surveillance (2022, October 29). High-Dose Influenza Vaccine (HD-IV) Compared with Standard Dose Influenza Vaccine (sIV) for Older Adults \u226565 Years to Prevent Influenza, Influenza-Related Complications or Mortality. Available online: https:\/\/www.ncirs.org.au\/sites\/default\/files\/2022-05\/HD%20vs%20sIV%20SoF%20EP%20E2D_March%202022_Final.pdf."},{"key":"ref_62","unstructured":"National Centre for Immunisation Research and Surveillance (2022, October 29). MDCK Cell-Derived Influenza Vaccine Compared to Standard Dose Egg-Based Influenza Vaccine in People Aged \u226518 Years. Available online: https:\/\/www.ncirs.org.au\/sites\/default\/files\/2022-05\/cIIV%20vs%20eIIV%20adults%20SoF%20EP%20E2D%20tables_March%202022_Final.pdf."},{"key":"ref_63","unstructured":"National Centre for Immunisation Research and Surveillance (2022, October 29). Summary of Findings: MF-59 Adjuvanted Influenza Vaccine Compared with Standard Dose Influenza Vaccine for People Aged \u226565 Years. Available online: https:\/\/www.ncirs.org.au\/sites\/default\/files\/2020-11\/Grade%20table%20-%20Adjuvanted%20influenza%20vaccine%20Vs%20standard%20dose%20influenza%20vaccine%20SoF%20EP%20E2D%20tables_Final.pdf."},{"key":"ref_64","unstructured":"ACIP (2022, October 29). GRADE: Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged \u226565 Years, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/influenza-older-adults.html."},{"key":"ref_65","unstructured":"ECDC (2022, October 29). European Centre for Disease Prevention and Control. Systematic Review of the Efficacy, Effectiveness and Safety of Newer and Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory Confirmed Influenza in Individuals Aged 18 Years and Over. Stockholm: ECDC. Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/seasonal-influenza-vaccines-systematic-review-efficacy.pdf."},{"key":"ref_66","unstructured":"Public Health Agency of Canada (2022, October 29). Literature Review Update on the Efficacy and Effectiveness of high-Dose (Fluzone\u00ae\u00ae High-Dose) and MF59-Adjuvanted (Fluad\u00ae\u00ae) Trivalent Inactivated Influenza Vaccines in Adults 65 Years of Age and Older. Available online: https:\/\/publications.gc.ca\/site\/eng\/9.852907\/publication.html."},{"key":"ref_67","unstructured":"(NACI), National Advisory Committee on Immunization (2022, October 29). Supplemental Statement\u2014Mammalian Cell Culture-Based Influenza Vaccines. Available online: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/mammalian-cell-culture-based-influenza-vaccines\/naci-sppl-stmt-ammalian-cell-based-influenza-vaccines-en.pdf."},{"key":"ref_68","unstructured":"Institute, R.K. (2022, October 29). Anlage zum Epidemiologischen Bulletin Nr. 1|7. Januar 2021 (Online Vorab). Available online: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/01_21_Anhang.pdf?__blob=publicationFile."},{"key":"ref_69","unstructured":"Alde\u00e1n, J.\u00c1., Hevia, A.C., Cenoz, M.G., Sanz, I.J., Marg\u00fcello, E.R., Herrero, F.S., Astiz, T.V., and Rojas, A.G. (2022, October 29). Revisi\u00f3n y An\u00e1lisis de las Evaluaciones P\u00fablicas de Organismos Internacionales Sobre los Niveles de Evidencia de las Nuevas Vacunas Antigripales. Available online: https:\/\/www.vacunas.sanofipasteur.es\/dam\/jcr:c7b41ade-00cd-458f-8d61-98828c46b8dd\/Resumen_analisis_organismos_internacionales.pdf."},{"key":"ref_70","unstructured":"EMA (2022, October 29). Guideline on Influenza Vaccines. Non-Clinical and Clinical Module., Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/influenza-vaccines-non-clinical-clinical-module_en.pdf."},{"key":"ref_71","unstructured":"(NACI), National Advisory Committee on Immunization (2022, October 29). Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022\u20132023. Available online: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/vaccines-immunization\/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2022-2023\/naci-2022-2023-statement.pdf."},{"key":"ref_72","unstructured":"Grohskopf, L. (2022, October 29). Influenza Vaccines for Persons Aged >65 Years: Evidence to Recommendations (EtR) Framework, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2022-06-22-23\/03-influenza-grohskopf-508.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022\u20132023 Influenza Season","volume":"71","author":"Grohskopf","year":"2022","journal-title":"MMWR Recomm. Rep."},{"key":"ref_74","unstructured":"T, B.-S. (2022, October 29). DANFLU-1: High-Dose vs. Standard-Dose Influenza Vaccine in Elderly Adults. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/08\/25\/19\/13\/sat-339am-DANFLU-1-esc-2022."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.vaccine.2020.09.004","article-title":"Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis","volume":"39","author":"Lee","year":"2021","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41541-022-00526-5","article-title":"Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: Cross-sectional study 2020-21, Israel","volume":"7","author":"Kuodi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999\u20132018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1097\/MD.0000000000000831","article-title":"Respiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities: An Observational Study","volume":"94","year":"2015","journal-title":"Medicine"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Fleming, D.M., Taylor, R.J., Lustig, R.L., Schuck-Paim, C., Haguinet, F., Webb, D.J., Logie, J., Matias, G., and Taylor, S. (2015). Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1218-z"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"ofw270","DOI":"10.1093\/ofid\/ofw270","article-title":"Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997\u20132012","volume":"4","author":"Pastula","year":"2017","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory syncytial virus (RSV): A scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijid.2020.11.185","article-title":"Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: Comparison with seasonal influenza","volume":"103","author":"Atamna","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40121-020-00387-2","article-title":"Current State of Respiratory Syncytial Virus Disease and Management","volume":"10","author":"Chatterjee","year":"2021","journal-title":"Infect Dis. Ther."},{"key":"ref_84","first-page":"2049936119865798","article-title":"Respiratory syncytial virus: Diagnosis, prevention and management","volume":"6","author":"Barr","year":"2019","journal-title":"Ther. Adv. Infect Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Volling, C., Hassan, K., Mazzulli, T., Green, K., Al-Den, A., Hunter, P., Mangat, R., Ng, J., and McGeer, A. (2014). Respiratory syncytial virus infection-associated hospitalization in adults: A retrospective cohort study. BMC Infect. Dis., 14.","DOI":"10.1186\/s12879-014-0665-2"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Chorazka, M., Flury, D., Herzog, K., Albrich, W.C., and Vuichard-Gysin, D. (2021). Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253161"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to a respiratory syncytial virus vaccine","volume":"125","author":"Mejias","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1016\/j.vaccine.2017.09.092","article-title":"Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"ref_90","unstructured":"Mazur, N.I., Terstappen, J., Baral, R., Bardaji, A., Beutels, P., Buchholz, U.J., Cohen, C., Crowe, J.E., Cutland, C.L., and Eckert, L. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape. Lancet Infect. Dis., 2022. in press."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against respiratory syncytial virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ison, M.G., Papi, A., Langley, J.M., Lee, D.G., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T.F., Van Zyl-Smit, R.N., Dezutter, N., and De Schrevel, N. (2022). A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults \u2265 60 Years of Age (YOA), Oxford University Press. Abstract IDWeek.","DOI":"10.1055\/s-0043-1767968"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"931242","DOI":"10.3389\/fpubh.2022.931242","article-title":"Impact of COVID-19 on viral respiratory infection epidemiology in young children: A single-center analysis","volume":"10","author":"Shen","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.15585\/mmwr.mm7140a1","article-title":"Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses\u2014New Vaccine Surveillance Network, United States, 2016\u20132021","volume":"71","author":"Perez","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1080\/22221751.2021.2000892","article-title":"Re-emergence of invasive pneumococcal disease (IPD) and increase of serotype 23B after easing of COVID-19 measures, Switzerland, 2021","volume":"10","author":"Casanova","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Rios-Silva, M., Trujillo, X., Huerta, M., Benites-Godinez, V., Guzman-Esquivel, J., Bricio-Barrios, J.A., Mendoza-Cano, O., Lugo-Radillo, A., and Murillo-Zamora, E. (2022). Reemerging Influenza Virus Infections during the Dominance of the Omicron SARS-CoV-2 Variant in Mexico. Pathogens, 11.","DOI":"10.3390\/pathogens11101181"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1152\/physiol.00035.2015","article-title":"Sex and Gender Impact Immune Responses to Vaccines Among the Elderly","volume":"30","author":"Fink","year":"2015","journal-title":"Physiology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","article-title":"Fourth Dose of BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting","volume":"386","author":"Magen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_99","unstructured":"Link-Gelles, R. (2022, October 29). Association between COVID-19 mRNA Vaccination and COVID-19 Illness and Severity during Omicron BA.4 and BA.5 Sublineage Periods. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.10.04.22280459v1."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1016\/S2666-5247(21)00157-9","article-title":"Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK","volume":"2","author":"Nadesalingam","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Davis-Gardner, M. (2022, October 29). mRNA Bivalent Booster Enhances Neutralization against BA.2.75.2 and BQ.1.1. Available online: https:\/\/europepmc.org\/article\/ppr\/ppr565823.","DOI":"10.1101\/2022.10.31.514636"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41565-022-01129-w","article-title":"Characterization of nanoparticles-based vaccines for COVID-19","volume":"17","author":"Guerrini","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/14760584.2019.1588727","article-title":"The burden of pertussis in older adults: What is the role of vaccination? A systematic literature review","volume":"18","author":"Kandeil","year":"2019","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_104","first-page":"50","article-title":"Isolation and characteristics of the plasma membrane fraction from the swine myometrium","volume":"58","author":"Kondratiuk","year":"1986","journal-title":"Ukr. Biokhim. Zh."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1080\/21645515.2020.1738168","article-title":"Pertussis in high-risk groups: An overview of the past quarter-century","volume":"16","author":"Jenkins","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/15412555.2021.1899155","article-title":"Burden of Pertussis in COPD: A Retrospective Database Study in England","volume":"18","author":"Aris","year":"2021","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/JAA.S335960","article-title":"Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England","volume":"15","author":"Bhavsar","year":"2022","journal-title":"J. Asthma Allergy"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:22Z","timestamp":1760119522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["antibiotics12010138"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12010138","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}